The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Area under the curve from time zero to last quantifiable concentration (AUC0-last)
Timeframe: Pre-dose to day 11
Area under the curve from time zero to extrapolated infinite time (AUC0-inf)
Timeframe: Pre-dose to day 11
Maximum observed plasma concentration (Cmax)
Timeframe: Pre-dose to day 11
Observed plasma concentration at the end of the dosing interval (C24)
Timeframe: Pre-dose to day 11
Time to reach maximum observed plasma concentration (Tmax)
Timeframe: Pre-dose to day 11
Plasma elimination half-life (T1/2)
Timeframe: Pre-dose to day 11